Program of the 4th International Workshop on
Waldenström's Macroglobulinemia

June 25-27, 2007
Kos 2007

Download the Kos Scientific Program as a .pdf file
Choose a Day
1 - 2 - 3 - 4

08:00

R.A. Kyle (USA)

Indications For Treatment And The Role Of Alkylating Agents In Waldenstrom’s Macroglobulinemia (WM)

08:20

V. LeBlond (France)

Role Of Purine Analogs In Front-Line Treatment Of Waldenstrom’s Macroglobulinemia

08:40

D.M. Weber (USA)

Rituximab Alone or in Combination in the Frontline Treatment of Waldenstrom’s Macroglobulinemia

09:00

M.A. Gertz (USA)

Overview In Salvage Treatment In Waldenstrom’s Macroglobulinemia

09:20

A. Anagnostopoulos (Greece)

The Role Of Autologous Transplantation In Waldenstrom’s Macroglobulinemia

09:40

S.P. Treon (USA)

Novel Agents in the Treatment of Waldenstrom’s Macroglobulinemia: Update of WMCTG Clinical Trials

10:30

I. Ghobrial (USA)

Proteomic Analysis In Waldenstrom Macroglobulinemia

10:50

N.C. Gutierrez (Spain)

The gene expression signature of clonal cells from Waldenstrom's Macroglobulinemia: differences and commonalities with the normal cell counterpart and other related lymphoproliferative disorders

11:05

E. Hatjiharissi (USA)

Gene expression profiling of Waldenstrom's Macroglobulinemia reveals genes that may be related to disease pathogenesis

11:20

E. Hatjiharissi (USA)

Novel splice variant transcript of Siva in Waldenstrom's Macroglobulinemia

11:35

S. Adamia (USA)

Aberrant post-transcriptional regulation of TNF family members and their adaptor molecules essential to B-cell growth and survival in Waldenstrom's Macroglobulinemia

11:50

B.T. Ciccarelli (USA)

The functional role of CD27-CD70 interactions in Waldenstrom's Macroglobulinemia

12:05

A. Anagnostopoulos (Greece)

Serum concentrations of angiogenic cytokines in Waldenstrom's Macroglobulinemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity

12:20

J. Soumerai (USA)

Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenstrom's Macroglobulinemia

12:35

C. Kyriakou (UK)

Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom's Macroglobulinaemia (WM). An analysis of 106 cases from the european bone marrow registry (EBMT)

12:50

X. Leleu (USA)

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's Macroglobulinemia (WM) patients treated with nucleoside analogues

13:05

A.D. Wechalekar (UK)

Clinical Profile And Treatment Outcome In 103 Patients With AL Amyloidosis Associated With IgM Paraproteinaemia

****

A.M. Roccaro (USA)

Resveratrol exerts antiproliferative effect and induces apoptosis in Waldenström's Macroglobulinemia

****

Z.R. Hunter (USA)

Genomic mutations in the April/Taci/Traf pathway in Waldenstrom'as Macroglobulinemia